Alkem Laboratories (NSE:ALKEM) 3-Year EBITDA Growth Rate : 3.70% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Alkem Laboratories 3-Year EBITDA Growth Rate?

Alkem Laboratories's EBITDA per Share for the three months ended in Sep. 2024 was ₹74.22.

During the past 12 months, Alkem Laboratories's average EBITDA Per Share Growth Rate was 31.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 3.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 11.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alkem Laboratories was 30.20% per year. The lowest was 2.90% per year. And the median was 16.40% per year.

Competitive Comparison of Alkem Laboratories's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alkem Laboratories's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's 3-Year EBITDA Growth Rate falls into.

Alkem Laboratories 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Alkem Laboratories (NSE:ALKEM) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Alkem Laboratories 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Alkem Laboratories's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkem Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkem Laboratories Ltd (NSE:ALKEM) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

539523:India

Address

Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013

Website

https://www.alkemlabs.com

Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Alkem Laboratories Headlines

No Headlines